Clinical trial
Antiviral Activity and Safety of 3 Different Doses of Mifepristone in Hepatitis…
NCT00255177 · VGX Pharmaceuticals, LLC, Industry · Completed
Key facts
| NCT number | NCT00255177 |
|---|---|
| Title | Antiviral Activity and Safety of 3 Different Doses of Mifepristone in Hepatitis C Infected Patients |
| Official title | A Randomized, Open-label Phase II Trial of the Anti-HCV Activity and Safety of VGX-410 (Mifepristone) at 3 Dose Levels in HCV Infected Patients |
| Lead sponsor | VGX Pharmaceuticals, LLC, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Hepatitis C Virus Infection |
| Intervention type | Drug |
| Interventions | VGX-410 (Mifepristone), Placebo |
| Enrollment | 44 |
| Start date | Nov 1, 2005 |
| Primary completion | Sep 1, 2007 |
| Completion | Jan 1, 2008 |
| First posted | Nov 17, 2005 |
| Last update posted | Nov 3, 2009 |
| Countries | United States |
At a glance
- 1–9 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: